Tema Oncology ETF (NASDAQ:CANC) Short Interest Up 232.7% in January

Posted by Latisha Jones on Feb 12th, 2025

Tema Oncology ETF (NASDAQ:CANC – Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 16,300 shares, an increase of 232.7% from the January 15th total of 4,900 shares. Based on an average trading volume of 18,000 shares, the short-interest ratio is presently 0.9 days.

Tema Oncology ETF Stock Performance

Tema Oncology ETF stock traded up $0.22 during mid-day trading on Wednesday, reaching $24.96. 13,564 shares of the company were exchanged, compared to its average volume of 29,638. The firm’s 50-day simple moving average is $25.24 and its two-hundred day simple moving average is $27.25. Tema Oncology ETF has a twelve month low of $23.97 and a twelve month high of $30.11. The firm has a market cap of $63.65 million, a PE ratio of 26.86 and a beta of 1.11.

Tema Oncology ETF Announces Dividend

The business also recently disclosed a dividend, which was paid on Thursday, December 12th. Investors of record on Wednesday, December 11th were paid a $0.7283 dividend. The ex-dividend date was Wednesday, December 11th.

Institutional Investors Weigh In On Tema Oncology ETF

A hedge fund recently raised its stake in Tema Oncology ETF stock. Thrivent Financial for Lutherans grew its stake in shares of Tema Oncology ETF (NASDAQ:CANC – Free Report) by 25.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 399,509 shares of the company’s stock after buying an additional 80,133 shares during the period. Thrivent Financial for Lutherans owned 22.96% of Tema Oncology ETF worth $11,351,000 as of its most recent SEC filing.

Tema Oncology ETF Company Profile

(Get Free Report)

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.